Clinical trial
A Phase II Trial of Pembrolizumab and Cabozantinib in Patients With RM SCCHN
NCT03468218 is registered in ClinicalTrials.gov with Emory University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Pembrolizumab and Cabozantinib in Patients With RM SCCHN
- Lead sponsor
- Emory University
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- September 18, 2018
- Completion date
- October 29, 2026
- Enrollment
- 36 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic head and neck carcinoma, paranasal sinus squamous cell carcinoma, recurrent head and neck squamous cell carcinoma, recurrent hypopharyngeal squamous cell carcinoma, recurrent laryngeal squamous cell carcinoma, recurrent oral cavity squamous cell carcinoma, recurrent oropharyngeal squamous cell carcinoma, stage iv hypopharyngeal squamous cell carcinoma ajcc v7, stage iv laryngeal squamous cell carcinoma ajcc v7, stage iv oral cavity squamous cell carcinoma ajcc v6 and v7, stage iv oropharyngeal squamous cell carcinoma ajcc v7, stage iva hypopharyngeal squamous cell carcinoma ajcc v7, stage iva laryngeal squamous cell carcinoma ajcc v7, stage iva oral cavity squamous cell carcinoma ajcc v6 and v7, stage iva oropharyngeal squamous cell carcinoma ajcc v7, stage ivb hypopharyngeal squamous cell carcinoma ajcc v7, stage ivb laryngeal squamous cell carcinoma ajcc v7, stage ivb oral cavity squamous cell carcinoma ajcc v6 and v7, stage ivb oropharyngeal squamous cell carcinoma ajcc v7, stage ivc hypopharyngeal squamous cell carcinoma ajcc v7, stage ivc laryngeal squamous cell carcinoma ajcc v7, stage ivc oral cavity squamous cell carcinoma ajcc v6 and v7, stage ivc oropharyngeal squamous cell carcinoma ajcc v7, unresectable head and neck squamous cell carcinoma